Navigation Links
TrialNetworks Feasibility Survey™ App Gets ARIAD Pharmaceuticals Unprecedented 75% Response from Potential Clinical Trial Investigator Sites
Date:9/30/2013

(PRWEB) September 30, 2013

TrialNetworks reported that ARIAD Pharmaceuticals, Inc. streamlined clinical trial site selection with a 75% response rate from potential sites located in 15 countries for a pivotal Phase II oncology study, besting the gold standard response by 25%. ARIAD chose to implement TrialNetworks Feasibility Survey because the online app makes collecting structured information from potential or existing sites quick, efficient and pain-free. In addition, Feasibility Survey integrates with other apps in the TrialNetworks platform to ensure a seamless transition from feasibility to site activation, training, document management, and the entire study startup process.

The majority of feasibility surveys are conducted inefficiently – often using paper, standard office spreadsheet programs or, at best, broad consumer survey software – typically yielding illegible, illogical, delayed and incomplete responses. This places a significant burden on the sponsor and CRO study teams to manually track non-responses, chase domestic and global sites to fill in missing or incorrect answers, and attempt to analyze responses across multiple versions of inconsistent formats.

Feasibility Survey solves these challenges by enabling sponsors to deploy secure, intelligently designed and easy-to-use surveys which guide study coordinators through survey completion, ensuring all questions are appropriately answered. Response options are formatted as clear, interactive fields (e.g. multiple choice, ranking tasks, free text, etc.) and can include text or video to guide respondents and encourage completion. Email reminders, custom alerts and detailed reporting provides sponsors with transparency into the survey progress so they can follow up efficiently with key sites yet to respond.

ARIAD, headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transform
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TrialNetworks Customer to Present Results of Using Site Engagement Technology to Improve Study Operations and Patient Enrollment at Clinical Trial Optimization Conference
2. MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCalls Microscope
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
7. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics, today announced that ... Global Healthcare Conference in Miami, FL at the Loews Miami ... executive officer of Pfenex, will provide an overview ... on March 12th at 9:00 am ET. A live audio webcast ...
(Date:3/2/2015)...  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading ... today announced that it will release fourth quarter and ... March 10, 2015 after the close of the U.S. ... and webcast on Tuesday, March 10, 2015 at 4:30 ... results and recent corporate developments. For both ...
(Date:3/2/2015)... 02, 2015 Global Stem ... alliance with Shenzhen HANK Bioengineering Co., Ltd. and ... alliance will establish a stem cells training course ... in September 2015. , Shenzhen HANK is a ... award-winning scientist, microbiologist and virologist, to integrate research, ...
(Date:2/28/2015)... Increasing its efforts to resolve the GMO Controversy ... of The GMO TRUTH podcast on both ITunes and at ... its mission to discover the truth and change the world. ... the truth about the GMOs in our food supply,” adds ... is an expansion of the documentary/investigative film-making methodology in place ...
Breaking Biology Technology:Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3The Walk a Mile Project Launches “GMO Truth” Podcast 2
... Studies show that up to 30% of coffees ordered as "decaf" contain ... the first do-it-yourself caffeine test strip from Silver Lake Research, the leader ... ... (PRWEB) November 12, 2008 -- Ever wonder whether the coffee you had ...
... Md., Nov. 12 MaxCyte, Inc.,the pioneer in ... will be hosting a live discussion with industry ... for drug discovery.,The discussion is open to the ... November 13th from 2:00-3:00EST., One of the ...
... 12 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX: SDI) today ... September 30, 2008., "In September, Spectral took ... strategy to align its diagnostic with a therapeutic ... Toray Industries Inc., to key,terms for the exclusive ...
Cached Biology Technology:Is Your Decaf Really Decaf? Use New "D+CAF (tm) Caffeine Test Strips" to Know for Sure 2MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery 2Spectral announces third quarter 2008 results 2Spectral announces third quarter 2008 results 3Spectral announces third quarter 2008 results 4Spectral announces third quarter 2008 results 5Spectral announces third quarter 2008 results 6Spectral announces third quarter 2008 results 7Spectral announces third quarter 2008 results 8
(Date:2/24/2015)... This report analyzes the worldwide markets for Face and Voice Biometrics ... Biometrics. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , Middle ... Latin America . Annual estimates and forecasts are provided ... is provided for these markets. Market data and analytics are derived ...
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... December 13, 2010 The American Society for Cell ... Open Microscopy Environment (OME), today announce the launch of ... Meeting of the American Society for Cell Biology. In ... through the National Institutes of Health,s (NIH) Grand Opportunities ...
... Global health experts today published a landmark collection ... on the experience of countries, companies and organizations ... homegrown drugs, vaccines, diagnostics and other creative scientific ... chronicles the triumphs and troubles of entrepreneurs, institutes ...
... Research published today identifies two genetic variants that ... disease. The study provides clues to the origin of ... impact on the quality of life of sufferers. ... Wellcome Trust Centre for Human Genetics and the Nuffield ...
Cached Biology News:ASCB launches 'The Cell: An Image Library' to inspire discovery and improve human health 2Studies detail triumphs, troubles of African innovators creating products for local health needs 2Studies detail triumphs, troubles of African innovators creating products for local health needs 3Studies detail triumphs, troubles of African innovators creating products for local health needs 4Studies detail triumphs, troubles of African innovators creating products for local health needs 5Studies detail triumphs, troubles of African innovators creating products for local health needs 6Studies detail triumphs, troubles of African innovators creating products for local health needs 7Studies detail triumphs, troubles of African innovators creating products for local health needs 8Studies detail triumphs, troubles of African innovators creating products for local health needs 9Studies detail triumphs, troubles of African innovators creating products for local health needs 10Studies detail triumphs, troubles of African innovators creating products for local health needs 11Studies detail triumphs, troubles of African innovators creating products for local health needs 12Studies detail triumphs, troubles of African innovators creating products for local health needs 13Studies detail triumphs, troubles of African innovators creating products for local health needs 14Studies detail triumphs, troubles of African innovators creating products for local health needs 15Studies detail triumphs, troubles of African innovators creating products for local health needs 16Studies detail triumphs, troubles of African innovators creating products for local health needs 17Studies detail triumphs, troubles of African innovators creating products for local health needs 18Studies detail triumphs, troubles of African innovators creating products for local health needs 19Genetic variants linked to increased risk of common gynecological disease 2
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Clone/PAD: ZMD.283. Immunogen: Fusion ... Specificity: Specific for ASIP/PAR-3 (atypical PKC ... This antigen is not related to ... Reactivity: Human Dog Xenopus (positive controls: ...
... C-1-tetrahydrofolate synthase, ... [Includes: Methylenetetrahydrofolate dehydrogenase ... cyclohydrolase (EC 3.5.4.9); ... 6.3.4.3)]. [Source:Uniprot/SWISSPROT;Acc:P11586] ...
...
Biology Products: